Compare F5 Inc (FFIV) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Heron Therapeutics Inc — how do they compare? F5 Inc trades at $479.83 (market cap $26.14B), while Heron Therapeutics Inc trades at $0.41 (market cap $68.01M). The key difference: F5 Inc is far larger — about 384.4× Heron Therapeutics Inc's market cap, and F5 Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Heron Therapeutics Inc for 35 Days on average.
| FFIV | HRTX | |
|---|---|---|
Market Cap | $26.14B | $68.01M |
Volume | 503,146 | 1,891,941 |
Sector | Technology | Health |
52-Week High | $479.83 | $1.49 |
52-Week Low | $223.99 | $0.27 |
Typical Hold Time | 38 Days | 35 Days |
Enterprise Value | $24.78B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $461.66, down 1.07% on the day, with a bullish technical outlook supported by moving averages and a strong fundamental backdrop. The company has consistently beaten earnings estimates, with Q2 2026 EPS of $4.73 surpassing the $4.00 consensus, and maintains robust profitability with a net income margin of 21.95%. Recent news highlights leadership in WAAP platforms and AI security partnerships, reinforcing growth prospects.
The stock offers upside potential driven by earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 36.78 suggest premium pricing. Key risks include competitive pressures and market volatility, while analyst consensus leans neutral with a $416.60 price target below the current price, indicating cautious optimism tempered by valuation concerns.
Heron Therapeutics (HRTX) trades at $0.36, down 8.15% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst sentiment remains overwhelmingly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX presents a high-risk opportunity with strong analyst support but fundamental challenges. The bullish technical setup and institutional confidence contrast with persistent losses and negative cash flow from operations. Investors face upside from potential operational improvements against the risk of continued financial underperformance in the competitive biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
